Quantcast

Latest The Michael J. Fox Foundation Stories

2014-09-09 12:28:04

- Only 28% of Parkinson's patients are currently receiving care from a Parkinson's specialist NEW YORK, Sept. 9, 2014 /PRNewswire-USNewswire/ -- A recent survey of more than 1,500 Parkinson's disease (PD) patients, caregivers and physicians reveals that information and specialized care can help patients become more engaged in their own treatment and in the Parkinson's community. http://photos.prnewswire.com/prnvar/20140909/144393 "When patients get to the right doctor, it...

2014-08-12 08:31:15

NEW YORK, Aug. 12, 2014 /PRNewswire-USNewswire/ -- Research projects from five groups active in Parkinson's research comprise the 2014 first half (1H 2014) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program projects are presented directly to industry groups who may wish to invest in further development. By connecting industry leaders with those studies ripe for investment, the...

2014-08-05 12:32:03

NEW YORK, Aug. 5, 2014 /PRNewswire-USNewswire/ -- Researchers need to know the genetic profiles of their study participants to understand more about how certain mutations manifest disease. But do the participants have to know? A group of 35 Parkinson's disease (PD) researchers published today in Genetics of Medicine the different answers to that question among sites investigating mutations in the LRRK2 gene, the greatest known genetic contributor to PD. Investigators from The Michael...

2014-08-04 23:09:13

FPRT Bio works closely with academic leaders and research organizations to advance the use of XPro1595 in the treatment of Parkinson’s disease. Dallas, Texas (PRWEB) August 04, 2014 FPRT Bio, a privately held clinical stage biopharmaceutical company, is developing XPro1595, a novel second generation inhibitor of soluble TNF, for the treatment of neurodegenerative diseases including ALS, MS, Parkinson’s and Alzheimer’s diseases. FPRT Bio works closely with academic partners and...

2014-07-31 12:29:21

AFFiRiS AG presents Phase I data on a first-of-its-kind treatment with support from The Michael J. Fox Foundation NEW YORK and VIENNA, July 31, 2014 /PRNewswire/ -- AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing. The Michael J. Fox...

2014-07-29 08:33:46

VIENNA, July 29, 2014 /PRNewswire/ -- What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community. When: Thursday, July 31, 2014 11.00 am EST (Eastern Standard Time) 03.00 pm UTC...

2014-07-28 08:30:24

ATLANTA, July 28, 2014 /PRNewswire-USNewswire/ -- RaceTrac announced that its cumulative giving to The Michael J. Fox Foundation for Parkinson's Research has exceeded $1 million. This milestone is due in large part to the continued efforts of their team members who have executed various initiatives over the years encouraging the community to participate in and support a worthy cause. "In four short years, RaceTrac has shown incredible generosity and commitment not only financially...

2014-07-24 08:35:23

VIENNA, July 24, 2014 /PRNewswire/ -- What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community. When: Thursday, July 31, 2014 11.00 am EST (Eastern Standard Time) 03.00 pm UTC...

2014-07-22 12:30:17

Initiative to optimize patient care spearheaded by AbbVie and The Michael J. Fox Foundation to visit 11 cities in 2014 NEW YORK, July 22, 2014 /PRNewswire-USNewswire/ -- National Parkinson's organizations are working together to help provide Parkinson's patients and caregivers with knowledge and support to optimize their care through the "Partners in Parkinson's" strategic health initiative launched by The Michael J. Fox Foundation and AbbVie. Partners in Parkinson's offers...

2014-06-26 16:23:38

Paper Addresses Challenges and Explores Opportunities to Stimulate Repurposing of FDA-Approved Drugs for Alzheimer's, Parkinson's and Related Diseases NEW YORK, June 26, 2014 /PRNewswire-USNewswire/ -- A new peer-reviewed publication from the Alzheimer's Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'